Market news

During the lightning round of the August 26 Mad Money episode, a caller asked whether it is time to “cut it off” or if Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has more potential given that they bought the shares at $30 and the stock is now above $60. In response, Jim Cramer said: I think you take […]

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your

David Krempa, Chief Business Officer, on August 24, 2026, sold 25,000 shares in Eton Pharmaceuticals

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Revenue surged 99% year-over-year on HEMANGEOL relaunch and rare disease portfolio growth.

Eton Pharmaceuticals (ETON) has become a focus for investors after its second quarter 2026 report, which showed US$37.59 million in revenue, US$11.58 million in net income, and a shift from loss to earnings per share. See our latest analysis for Eton Pharmaceuticals. The strong Q2 results and raised 2026 guidance have coincided with a sharp re-rating in Eton Pharmaceuticals, with a 1 day share price return of 44.26% helping extend its year to date share price return to 261.99%, while the 3...

Eton's cure for an expensive valuation: a 99% sales growth rate.

Eton expects full-year 2026 revenue to exceed $145 million, up from its previous forecast of more than $120 million.

Eton Pharmaceuticals, Inc. posts record Q2 2026 results, raises revenue guidance, targets $500M peak sales & 35%+ EBITDA margins. Click to see the ETON Buy thesis.

Eton stock catapulted to a record high Friday after the biotech company smashed second-quarter sales forecasts.

Moby summary of Eton Pharmaceuticals, Inc.'s Q2 2026 earnings call

Top analysts changed outlook on top names. Mizuho raised price target for AIT from $355 to $400. See how analysts view AIT, ETON, PLGO, BRZE, VERI, POWL, AMAT, and YETI.

Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of +218.18% and +38.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025Q2 2026 fully diluted GAAP EPS of $0.35, non-GAAP fully diluted EPS of $0.43; EBITDA of $14.1 million, Adjusted EBITDA of $16.2 millionRaising full year revenue guidance, with 2026 revenue now expected to exceed $145 million, up from previous guidance of more than $120 millionRelaunched HEMANGEOL® May 1st, patient conversion completed ahead of scheduleAcquired late-stage product candidate ASN-001, ex

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Eton Pharmaceutcials Inc (ETON-Q) from The Globe and Mail including charting and trades.

ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timololComplementary product to HEMANGEOL® (propranolol hydrochloride) oral solution, positioning Eton, if approved, to treat full spectrum of infantile hemangioma patientsASN-001 Phase II/III trial results showed week 24 elimination or near-elimination rates of 56% (BID) and 42% (TID) compared with 15% for placeboAnticipate NDA submission in 2H 2027 for potential approv

DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2026 financial results on Thursday, August 13, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link: Click Here Webcast: Click He

FDA submission seeks to bring KHINDIVI to larger pediatric patient population within the adrenal insufficiency marketNew formulation successfully demonstrated bioequivalence to ALKINDI SPRINKLE®Submission allows for a potential first half 2027 approval of the expanded indication DEER PARK, Ill., July 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare di

Craig-Hallum on Tuesday lifted its price target on ETON to $62 from $40 and kept a Buy rating.

Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.